Currently, the genetically engineered mouse models whereby the NSCLC initiation and progression are driven by the oncogenic KRAS or BRAF mutations are used to study the molecular aspects of the disease [159]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.